Company Prices New HIV/AIDS Salvage Drug at $9,900 USD Per Patient Yearly Following FDA's Recent Approval of Isentress, Merck's New Integrase Inhibitor. AHF Decries Overall Price Spiral on New AIDS Drugs; Urges Restraint by Entire Pharmaceutical Industry in Pricing
LOS ANGELES, Oct. 15 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today criticized Merck and Co. Pharmaceuticals, for the announced price for its key new HIV/AIDS drug, Isentress (raltegravir), an integrase inhibitor approved by the Food and Drug Administration (FDA) Friday, and priced by the company at nearly $9,900 per patient yearly. Today's Kaiser Daily HIV/AIDS Report noted that Isentress is an integrase inhibitor that "...decreases HIV viral loads after 24 weeks of use among HIV-positive people who have not responded to other treatments," according to a study published in the April 14 online edition of the journal Lancet."
"We commend Merck for the development of this new HIV/AIDS drug that shows particular promise as a salvage therapy, but urge the company to reconsider its action and set the price of this lifesaving medicine so it is affordable," said Michael Weinstein, AIDS Healthcare Foundation President. "The steep cost of this new drug is symptomatic of the overall price spiral of AIDS drugs. As with many other AIDS drugs before it, the price is simply out of reach for most AIDS patients, and Merck and other companies' pricing for their AIDS drugs threatens to further limit the ability of Medicaid and AIDS Drug Assistance Programs nationwide to provide crucial medications to its patient populations."
According to a Reuters news article, "The company (Merck) said it would charge about $27 per day, or $9,855 annually, for the drug. Steep prices for AIDS drugs have been criticized by patients and advocacy groups, who say they deter use of lifesaving drugs."
In 2004, Roche & Trimeris created an international uproar when its drug
Fuzeon, also widely
'/>"/>
| SOURCE AIDS Healthcare Foundation Copyright©2007 PR Newswire. All rights reserved |